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From The Editor 
This editorial is important to me for several reasons. First 
it heralds the end of my clinical clerkship and second, this 
will be my last issue as editor of The Medical Journal. Both 
clinical clerkship and the editorial position have had their 
ups and downs, and both have had their elements of 
humour. 
"People" are what make medicine so much fun, and I 
have seen my share of "different" people this year. I will 
always fondly recall one evening at St. Joseph's emergency 
that I spent with an obese psychotic patient who was receiv-
ing "messages" from Audie Murphy (a familiar name if you 
watch old cowboy movies). This patient's agitation was so 
great that she could not be kept in an examining room . Con-
sequently, she spent a whole hour (prior to her transfer to 
LPH) walking in a big square about St. Joseph's emergency, 
receiving messages the whole time from Audie Murphy. I 
spent one hour of my clerkship walking behind this lady 
making sure she and other patients came to no harm - not 
my idea of what medicine would entail when I first applied 
three years ago. 
Family medicine was a "gold mine" when it came to en-
countering unusual patients. One patient in particular 
typified this. He was a skinny middle-aged fellow with a 
complaint of itching perianally and underneath his penis. It 
sounded straightforward to me but I asked a few more ques-
tions. 
"Do you have any more problems sir?" 
"Yes, I have had some funny feelings in my stomach". 
The patient delivered these words tentatively with a whim-
sical look on his face . He then proceeded to deny any G-1 
complaints other than this "funny feeling". My next ques-
tion was no more earthshaking than the first. 
by Steve Lundy 
"Any more problems?" 
"Yes, I've had some cold sweats over the last few weeks." 
These "cold sweats" turned out to be elusive as Liberals 
west of Ontario (or Windsor doctors who haven't opted out 
of O.H.I.P .). I gave it one more try. 
"Are these the only problems you have?" 
"Well, no. I have had a pulling feeling in my eyes the last 
few weeks ." 
Surprisingly, this patient did have a perianal rash. As to 
his other problems, who know~? 
This past year has been very educational. Let me share a 
few aphorisms with you based on a year's experience. If you 
wear white shoes you are halfway to being a surgeon. A 
flashy sport's car is equivalent to wearing white shoes. 
Psychiatrists smoke pipes. Psychologists smoke dope. 
Medical students get married-surgical and obstetrical 
residents get divorced. "Sandwich rounds" are the best 
teaching rounds. Lab medicine induces fatigue (as do the 
first two years of medicine). Rashes are not meant to be 
identified and can always have steroid cremes applied. 
Steroid cremes are not known to cause cancer (yet!). An 
endorphin-a-day will keep the blues away (prostaglandins 
used to be capable of this). Everyone deserves a trial of 
Cimetidine. Every female patient has prolapsing mitral 
valve syndrome until proven otherwise. 
After these few "gems" let me say that this issue of the 
Journal is a good one. It includes a diversity of articles in-
cluding two very comprehensive and excellent articles -Dr. 
Yuzbe's review of contraception including what the future 
holds and Dr. Gowdey's look at the exciting new field of 
"endorphins". We hope you will read and enjoy this issue 
of the Journal. 
by Steve Lundy 
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Depression Today 
Confident Clinical Office Management 
SCIENTIFIC PROGRAM: 
DEPRESSION TODAY is a learning system for continuing medical education . Its broad goal is to help physicians 
gain the knowledge needed to provide quality care to patients with depression. 
Highly practical in concept, the system focuses on depression issues that are directly applicable to a physician's 
everyday clinical practice. 
This program incorporates film presentations and monographs having self-evaluation tests . 
PART 1: RECOGNIZING AND DIAGNOSING DEPRESSION- 30 Minutes 
This unit provides a practical approach which can be integrated into the routine interview and the examination 
of patients. 
PART 2: MANAGINu • rfE ACUTE EPISODE AND FOLLOW-UP PHASE- 30 Minutes 
In this unit, physicians learn how to treat depression using currently accepted pharmacotherapy and psycho-
therapeutic measures. 
PART 3: SPECIAL CASES IN THE PHARMACOLOGIC MANAGEMENT OF DEPRESSION - 30 Minutes 
This unit, of particular interest to psychiatrists as well as to other physicians , deals with pharmacologic man-
agement of the more complex cases of depression. 
ACCREDITATION: 
Approved for 1 credit hour in Category 1 for the Physician 's Recognition Award of the American Medical Associa-
tion for each film and 9 credit hours for completion of the monographs. 
Merrell THE WM. S. MERRELL COMPANY Division of Richardson-Merrell (Canada) Ltd. 
2 Norelco Drive, Weston, Ontario M9L 1 R9 
To schedule this Depression Program for your 
next meeting CALL OR WRITE 
ED KENNY 
31 Park Avenue 
St. Thomas 
631-4079 
Merrell Medical Specialities include 
AVC, Bendectin, Bentylol, Biogastrone, Cepacol, Duogastrone, 
Tace, Tenuate, Chronulac, Cephulac, Norpramin 
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Medical Elective in Taiwan 
This past year, the Foreign Medical 
Elective Programme at Western attracted 
many members of the Fourth Year 
class. Opportunities to observe the prac-
tice of medicine were found in places 
such as Tanzania, Sumatra, Scotland, 
New Zealand, New Guinea, Bangladesh, 
India , and in many different states of 
the United States . I myself, along with 
my wife Victoria, spent three months at 
a mission hospital in Hualien, Taiwan . 
In the rest of this article I would like to 
touch on some of the highlights of our 
experiences there . 
For the average medical student , even 
with the recent airfare "warfare", long 
distance travelling costs are prohibitively 
expensive . Fortunately for us some 
generous funding for the elective came 
from the Mennonite Medical Associa-
tion. In addition to considerable finan-
cial assistance, they also arranged my 
placement at the Mennonite Christian 
Hospital in Hualien where we were pro-
vided in an apartment on the hospital 
compound absolutely free. 
Language difficulties became im-
mediately apparent. My wife attempted 
to ease the problem in one way by pro-
viding English lessons to nurses four 
days a week, lessons the hospital ad-
ministration enthusiastically supported. I 
was left to struggle to communicate 
through interpreters. The medical staff 
was made up of North Americans 
primarily, but the residents and internes 
were Chinese whose English was only 
just comprehensible. Nurses, and of 
course, patients, could not speak any 
English . Indeed, many patients did not 
even speak Mandarin , the official 
language in Taiwan since 1949. As a 
result situations often arose where more 
than one interpreter was needed . A sim-
ple question like " Do you smoke?" 
resulted in much discussion at each step 
and a final answer " No." This left me 
wondering what priceless data was being 
lost at each step in the translation pro-
cess. This led to frustration, a feeling I 
solved by participating in the hospital 's 
public health program and Mobile 
clinics . 
The hospital offered services in all of 
the major special ties except psychiatry 
(it didn't seem to exist as a di scipline 
except in the largest cities). I spent 
about equal time in each, interspersed 
with a great deal of time on Mobile 
clinics. The public health nurses were 
concentrating their efforts on parasi tes 
and birth control and I found that 
although my usefulness in the hospital 
was limited , I could be of considerable 
aid to them in the vi llages. Incidentally , 
I think it should be kept in mind when 
considering a foreign elective how much 
language barriers can prevent participa-
tion . By the time a medical student is in 
fourth year , he or she probably would 
like a little more than just observer 
status. 
The public health program I became 
involved with proved to be particularly 
enjoyable because of the necessi ty to 
work with people in their homes, rather 
than in the conspicuously "Western" 
edifice, the hospital. On one occasion 
we were fortunate to be invited to a 
wedding feast, although the bride and 
groom were total strangers to ourselves . 
Nevertheless we became the honoured 
guests, and were treated to a 
gastronomic delight of unfamiliar but 
highly palatable foods. These included 
cow's stomach soup, squid, another 
by David James Mathies 
Meds 79 
soup in which a duck was swimming 
whole (head, feet and all!), sweet bean 
and rice dishes, and hot spicy octopus. 
Such spontaneous friendliness and 
generosity was commonplace. More than 
once a compliment or admiring glance 
resulted in an instant gift. 
Politically, Taiwan was an interesting 
place in which to live. The recent 
developments in Sino-American relations 
have I'm sure attracted considerable 
alarm in Taiwan. The fact that both 
Chinas consider the other part of 
themselves and that each is determined 
to annex the other will surely complicate 
the issues . Taiwan, a country approx-
imately the size of Vancouver Island, 
with a population close to seventeen 
million , seems to be convinced that one 
day it will recover the mainland and 
restore it to their particular form of 
democracy . At least the daily newspaper 
there emphatically stated it was possible. 
Wherever one travelled expertly trained 
soldiers could even be seen marching 
and practicing their martial arts in a 
kind of frightening ballet. During my 
stay I found it increasingly easy to sym-
pathize with them, as recovery meant 
for many a return to homes and 
relatives left behind during the revolu-
tion . What will be the outcome of 
China's ideological struggle is certainly 
not yet a foregone conclusion. 
The lessons gained from this elective 
were multi-dimensional, covering a 
number of areas apart from medical ex-
periences. Because of this I would like 
to conclude by encouraging as many 
other fellow students in other classes to 
consider doing a foreign elective. For 
more in formation contact Dr. J. S. 
McKim . 
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Endorphins: 
Neither Panacea nor Teapot Tempest 
Just over three years ago a research 
team in Scotland' discovered a new kind 
of opioid substance which they called 
"enkephalin" because it was found in 
the head . These endogenous morphine-
like substances, contracted to "en-
dorphins", were quickly confi rmed by 
investigators in Sweden, the U.S. and 
England. The basic pharmacological 
studies leading to the finding of en-
dorphins and their receptors represent 
important achievements in neuroscience 
and may have a profound impact on 
widely-differing areas of clinical prac-
tice. My review is an attempt to 
describe some of the concepts and con-
tributions in this rapidly boiling field of 
research and also the potential for 
significant advances in treatment. 
-Goldstein2 states that the discovery of 
endogenous opioids followed an 
established tradition in pharmacology ex-
emplified by the discovery that 
acetylcholine is a neurotransmitter : first, 
observation of the paralyzing effects of 
the arrow poison curare; then studies of 
"receptive substance" in muscle and 
ganglia stimulated by nerve stim ulation 
or nicotine and blocked by curare; 
studies of chemical structure related to 
physiological activity; and finally the 
demonstration of chemical transmission 
and proof that acetyldtoline was the en-
dogenous ligand of Claude Bernard's 
"curare receptor" in muscle and 
Langley 's "nicotine receptor" in ganglia. 
Two prerequisites for discovery of 
neurotransmitters are the conviction that 
they exist and a suitable assay system 
for measuring them so that they may be 
puri tied and characterized. 
Like many other pivotal concepts, the 
idea that the brain might produce its 
own opiates did not arise from one 
brilliant flash of inspiration, but rather 
was the result of combined beams of 
light from widely divergent research 
fields over several years. Receptor phar-
macology, sometimes considered a 
relatively irrelevant game for academi-
cians, played a vital role. The availabili-
ty of sophisticated new apparatus and 
techniques opened up further avenues 
for research in the interactions between 
biogenic amines, endocrines and 
behaviour. Although it had been known 
for many years that the hypothalamus 
and pituitary are involved in responses 
of the organism to danger and stress, 
Page 6 
the multiplicity of actions of peptide 
substances in the brain has only recentl y 
been appreciated. In Holland, de Wied 3 
has found that pituitary-derived peptides 
have important effects on the acquisition 
and maintenance of avoidance behaviour 
in rats. His results implied that ACTH, 
MSH , etc . were deeply involved in learn-
ing. Other work~ showed that narcotic 
analgesics can increase the secretion of 
ACTH, growth hormone and that ovula-
tion is prevented in some species. 
Chronic administration of morphine in-
hibits the release of TSH, depresses the 
pituitary-adrenal response to stress and 
decreases gonadotropin and LH secre-
tion . Neurophysiological experiments 
showed that ACTH, MSH and 
vasopressin can antagonize some of the 
depressant effects of morphine on the 
excitability of central neuwns5 . 
Another apparently unrelated area of 
research which turned out to have great 
importance in the endorphin story was 
that of Li at Berkeley . During his in-
vestigations on the purification of 
ACTH from sheep pituitary in 1964 he 
found" a new hormone with some 
lipolytic act1v1ty; he named it beta 
lipotropin ( LPH) and determined that 
it had a 91 amino-acid chain, but no 
obvious function. Ten years later Li 
isolated 7 a substance from hundreds of 
camel pituitaries which a former student 
of his had sent from Iraq; this com-
pound was smaller than LPH and, 
like it, seemed to be a hormone without 
a use. Within two years it was in great 
demand and far more precious than 
gold. 
Other areas of research that led to 
more illumination on the role and prop-
erties of endogenous analgesic substances 
involved the mechanisms of pain relief. 
The sites of action and the effects of 
the natural and synthetic opioid drugs 
continued to be investigated by many 
groups, but although the results were 
often interesting and sometimes led to 
novel and exceedingly potent com-
pounds, their direct influence on clinical 
practice had been relatively minor. Mar-
tin and his colleagues8 did demonstrate 
stereo-specific and antagonist-reversible 
polysynaptic blockade in the spinal cord, 
but the complexity of the neural 
mechanisms continued to plague in-
vestigators. The notion of a central pain 
pathway was apparently conceived by 
by C. W. Gowdey, M.D. 
the Aristotelian school as long ago as 
the fourth century B.C . and spinal 
pathways had actually been studied by 
Galen, but as recently as 1975 Akil 
wrote9 that the pain pathways into the 
brain are not well understood beyond 
the level of the thalamus . Their termina-
tions in the cerebral cortex are 
unknown, and their interactions with 
limbic structures remain obscure. Even 
the mechanisms involved in the simplest 
withdrawal reflex at the spinal cord 
level are complex. Even with all the re-
cent research activity her statements are 
still true today . 
For many years neurosurgeons have 
recognized the fundamental importance 
of inhibitory processes in the function 
of the nervous system and have reported 
varying success in pain relief from 
stimulation of peripheral nerves or after 
central stereotactic operations . Some of 
these procedures were based upon the 
gate control theory of Melzack and 
Wall' 0 which emphasized interactions 
among different types of sensory input 
because of observations that non-painful 
stimuli could inhibit pain. Within the 
past few years Mayer , Liebeskind and 
Akil" 13 have accumulated evidence of 
a central pain suppressive system in-
cluding the mesencephalic central gray 
and peri ventricular gray matter, elec-
trical stimulation of which leads to 
analgesia in experimental animals and 
relief of chronic pain in some patients . 
The analgesia can be blocked by nalox-
one'4 16 and cross-tolerance to morphine 
occurs. This observation represents an 
important focusing of light on the prob-
lem of pain. The role of the pituitary in 
pain control is sti ll not understood, but 
the remarkable report of Moricca18 in 
which "pain relief was complete, im-
mediate and long-lasting" in 605 of 687 
patients with advanced malignancy 
treated by chemical hypophysectomy 
begs for explanation. 
In the early 1960's Kosterlitz and his 
colleagues at Aberdeen began a series of 
studies of the peripheral effects of 
opi~tes with an ingenious preparation 
dev1sed by Paton which involved elec-
trical stimulation of isolated strips of 
guinea pig ileum or mouse vas deferens. 
!h~y. found that morphine derivatives 
1~1b1ted the neurally-mediated contrac-
tions of these tissues; the inhibition in-
volved specific receptor sites; it was 
blocked by the specific narcotic an-
tagonist naloxone, and somewhat sur-
prisingly, the ability to prevent contrac-
tions in these isolated smooth muscle 
preparations was parallel to the potency 
of these narcotics as analgesics 17 • 
In 1976 Goldstein first demonstrated 1 8 
the existence of stereospecific opiate 
receptors in mouse brain fractions using 
radio-isotope labelling techniques. This 
finding that opiates act on brain cells by 
combining in a highly selective manner 
with particular protein molecules on 
their membranes was of great 
significance not only intrinsically, but 
also because it led to the question: since 
opiates are not a normal body consti-
tuent, why does the brain possess recep-
tors for them? The question became 
even more pertinent after further work 
with powerful, radioactive narcotic 
agonists and antagonists by Snyder's 
group at John Hopkins' 9 20 , Simon's at 
New York University21 and Terenius's at 
Uppsala22 soon confirmed that indeed 
specialized opiate receptors did exist on 
the membranes of nerve cells in the 
brain and spinal cord in many 
vertebrate species. The affinity of mor-
phine and other opiate drugs for these 
receptors seemed to parallel closely their 
pharmacological potency as analgesics23 , 
leading to the conclusion that somehow 
analgesic potency of opiate drugs could 
be correlated with their ability to bind 
specifically to opiate receptors in either 
ileum24 or brain21 • 
Where are these opiate receptors 
localized? Using auto-radiographic 
techniques groups of investigators in the 
U.S. 19 21 25 and Sweden22 mapped out 
the differential distribution within the 
central nervous system and found 
similar regional variations in the density 
of receptors in several mammalian 
species. Pert found that opiate receptors 
existed in creatures as far down the 
developmental ladder as the hagfish28 , 
which is thought to have been in the 
seas for some 350 million years, a fact 
that made it highly improbable that a 
special nerve pathway had been 
developed to interact only with an ex-
tract of oriental poppy. That receptors 
occur in all vertebrates but not in 
subvertebrate species suggests that both 
the receptors and the endorphins are ad-
vanced evolutionary adaptations with 
important survival value2 • 
The pattern of distribution of recep-
tors is strongly correlated with areas of 
the nervous system known to be involv-
ed in the perception and processing of 
pain. According to Goldstein27 , the 
clearest example of a mechanism involv-
ing these receptors is in the spinal cord, 
the first relay in the pain pathway. The 
dorsal root ganglion cell is a bipolar 
neuron, sending a long axon out to the 
periphery, the terminal of which acts as 
primary pain receptor. The other axon 
enters the dorsal horn of the spinal cord 
where it synapses in the substantia 
gelatinosa - a region rich in opiate 
receptors (and in enkephalin). There is 
evidence now that another peptide, 
substance P, is the transmitter of the 
primary afferent neuron. It is believed 
that short interneurons working through 
enkephalins modulate the output of 
substance P and thus are capable of 
suppressing noxious inputs at the 
primary relay . Downflowing pathways 
originating in the periaqueductal gray 
and other brain stem structures activate 
these neurons, presumably through the 
neurotransmitter serotonin28 • In this way 
stimulation in the brain stem would act 
through these pathways to cause 
enkephalin release and inhibition of pain 
in the spinal cord. It is obvious from 
inspection of the tables21 showing the 
regional distribution of these receptors 
in monkey and human brains that by 
far the highest concentration is in com-
ponents of the limbic system or regions 
associated with it: amygdala , septal 
nuclei, peri ventricular gray matter , hip-
pocampus, centromedian and dorsome-
dian nuclei of thalamus , preoptic and 
supraoptic nuclei, temporal lobe, etc . 
This system is obviously involved in 
poorly-localized and emotionally-
influenced pain . 
Elsewhere in the brain stem, opiate 
receptors are found in nuclei associated 
with afferents not carrying pain25 , a 
fact that may explain such effects of 
morphine as suppression of cough, or-
thostatic hypotension29 , reduction of 
gastric secretion, libido and urinary out-
put and the nausea and vomiting due to 
stimulation of the medullary 
chemoreceptor trigger zone30 • 
Meanwhile, microinjection techniques 
in animals revealed that the most impor-
tant sites for the anti-nociceptive effect 
of morphine are in the periventricular-
periaqueductal gray matter extending 
from the lower portion of the third ven-
tricle along the aqueduct into the fourth 
ventricle . More lateral and less sensitive 
was an area ranging from the substantia 
nigra through the red nucleus up to the 
intralaminar region of the thalamus 31 • 
Pert pointed out32 the strong positive 
correlation in the brain between those 
sites most effective for morphine-
induced analgesia and the areas rich in 
opiate receptors. 
With all these results accumulating it 
is not suprising that a race developed 
among neuroscientists to discover the 
endogenous opiate. Hughes described33 a 
crude extract from 300 g of pig brain 
which, when tested on the isolated 
mouse vas deferens preparation, gave 
evidence of opiate activity . At the same 
meeting Terenius announced the proper-
ties of an endogenous ligand that had 
been isolated in his laboratory in 19743 • 
from acid-water extracts of rat or calf 
brain homogenates using a binding-assay 
procedure. 
First prize went to the Hughes and 
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Kosterlitz team; they reported' in Nature 
in late 1975 the isolation and structures 
of the first two endogenous opiates, 
from pig brain, and called them 
methionine-enkephalin and leucine-
enkephalin. Both were pentapeptides 
and, like morphine, could be bioassayed 
because they inhibited electrically-
induced contractions of the vas deferens . 
The authors noted that a replica of 
methionine-enkephalin could be found in 
the chain of 91 amino acids which make 
up Li's giant (3- lipotropin. This report of 
the exact structure of the enkephalins 
caused a veritable explosion of activity. 
In the meantime, Smyth's group35 at 
the National Institute for Medical 
Research in Britain had isolated and 
identified constituent fragments of 
lipotropin from the pituitary. Not only 
did the long-recognized (3- MSH occur as 
an intact peptide, but so could their "C-
fragment"(i.e. (:J· LPH-(61-91)). Realising 
from a discussion with Hughes that the 
structure of met-enkephalin had the 
same sequence as that at the N-terminus 
of their "C-fragment", they postulated 
that the latter might be the precursor of 
met-enkephalin. Injection of this 
material into the third ventricle of the 
cat induced marked analgesia (with a 
potency about 100 times that of mor-
phine). The hectic pace of this fast-
moving research may be appreciated 
from the report36 that on the west coast 
of California Goldstein read the amino-
acid sequence as reported in the 
Hughes' paper to Li over the telephone . 
Li realized that the molecule was iden-
tical with that terminal part of his 30-
amino acid "useless" camel pituitary 
hormone. It was soon found to have 
powerful analgesic activity37 • This com-
pound later turned out to be identical 
with beta-endorphin. Goldstein's group 
reported the presence of an endorphin in 
a commercially available ACTH 
extract36 and in bovine and rat pituitary 
glands39 • Guillemin and his colleagues 
also isolated endorphins with mor-
phinomimetic actlVlty from 
hypothalamus-neurohypophysial extracts 
and established their structures•0. Four 
endorphins were recognized, all contain-
ing met-enkephalin and all present in 
(3-lipotropin: a -endorphin is (3 -LPH 
(61-76); (3 -endorphin is (61-91); Y -
endorphin is (61-77) and ll is (16-87). 
Though they differ structurally by only 
one amino acid, alpha and gamma-
endorphin have opposite effects: c~ -
endorphin produced short-term analgesia 
and tranquilization not unlike that after 
large doses of enkephalin, but Y -
endorphin made animals violent, ir-
ritable, and apparently hypersensitive to 
pain4'. It thus seems that the same 
'prohormone' can give rise to agonist 
peptides (e.g. met-enkephalin, (3- -
endorphin) and antagonists (e.g. MSH 
and Y -endorphin). The ongm of 
leucine-enkephalin is till a mystery; it is 
present in amounts only 25-300Jo of met-
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enkephalin in pig, rabbit, guinea-pig, 
mouse and rat brains, but its precursor 
is unknown42 . 
The distribution of the enkephalins in 
the brain was studied by Kosterlitz's 
group42 by mouse vas deferens method 
of bioassay and by Snyder and his col-
leagues by immunohistochemical tech-
niques43 . As expected, they found that 
regional variations in tissue levels of 
enkephalins in the brain appeared to 
parallel the relative density Pert had 
reported of the opiate receptors. 
Enkephalins are localized in nerve ter-
minals and axons of systems that 
subserve integration of sensory informa-
tion, including pain. Both groups found 
that the two enkephalins are present in 
various parts of the brain, but in dif-
ferent proportions. Endorphins have also 
been isolated from brain tissue, but they 
are less widely distributed than are the 
enkephalins and are in much smaller 
concentrations than in pituitary where 
they are concentrated in the pars in-
termedia•• . Pituitary (3 -endorphin is 
probably not the source of brain en-
dorphin because hypophysectomy does 
not modify brain levels45 ; pituitary con-
tains little if any enkephalins••. 
(3 -endorphin and ACTH are con-
sidered originally to be part of a 31000 
dalton precursor glycoprotein 47 . 
Guillemin and Bloom demonstrated48 an 
equimolar secretion of endorphins and 
ACTH in several conditions (severe 
stress, addition of corticotropin-releasing 
factor to adenohypophysial cell cultures, 
cells from human ACTH-secreting 
tumors.) In vivo these secretions were 
antagonized by hypophysectomy or ad-
ministration of glucocorticoids. These 
authors suggest that the response of an 
organism to stress involves immediate 
secretion of pituitary hormones; some, 
like ACTH and growth hormone are 
concerned with somatotropic (metabolic) 
adaptive reactions, whereas other , like 
(3 -endorphin and (3 -MSH, are related 
to neurotropic or psychotropic adaptive 
reactions. 
Enkephalins are also present in the 
noradrenergic cells of the adrenal 
medulla and in autonomic ganglia, but 
their function is not known 49 . Those 
found in the guinea-pig ileum may be 
involved in regulating intestinal 
motility60 . Endorphin activity can be 
generated from (3 -LPH, which itself is 
devoid of opioid activity, by incubation 
with guinea-pig ileum or brain 
homogenates"'. But while it is 
postulated that met-enkephalin synthesis 
might proceed through (3 -LPH as 
precursor, there is no experimental 
evidence for this. 
Holaday et a/62 found that 
hypophysectomized rats are supersen-
sitive to the hypothermic effects of mor-
phine and (3 -endorphin. Guillemin41 
reported that whereas (3 -endorphin 
lowers body temperature, Y -endorphin 
raises it - an effect similar to that 
after met-enkephalin53 . Similar responses 
have recently been studied in our 
laboratory by Thornhill after most doses 
of heroin 5 4 and morphine••, and by 
Tepperman56 after met-enkephalin, but 
there is a delay in onset. Thornhill et 
a/57 also showed that repeated ad-
ministration of morphine or heroin led 
to pronounced feeding at the wrong 
time in the diurnal cycle. Brands et a/68 
later found that naloxone reduced the 
food intake of rats whether they had 
been fasted or were feeding spon-
taneously. (3 -endorphin induces extreme 
immobility and muscular rigidity68 and 
intracisternal injections, like morphine, 
can cause marked respiratory depression, 
temporarily reversed by naloxone60 . 
In 1976 Akil et a!"' reported that 
acute stress induced by intermittent foot-
shock produced an anti-nociceptive ef-
fect and a significant increase in en-
dogenous opiates in rats. With chronic 
stress opiate levels returned to control 
values. Arnir and Arnit62 of Concordia 
University showed that single or 
repeated daily sessions of immobilization 
stress in rats changed pain-related 
behaviour and they suggested that the 
endogenous system involved may be 
mediating the affective but not the sen-
sory factors of pain-related responses. 
These results are in accord with current 
pharmacological teaching re narcotic 
analgesics: in clinical doses pain 
tolerance is increased far more than 
pain thresholds. 
Gent and Wolstencroft28 applied mor-
phine, met-enkephalin and endorphin by 
iontophoresis to single neurons in the 
brainstem of cats. Neurons in the 
reticular formation of the medulla and 
pons and in the raphe nucleus were in-
hibited or unaffected by all three. In the 
midbrain many neurons were inhibited 
but some, particularly in the peria-
queductal gray, were excited by mor-
phine and endorphin, excitation by met-
enkephalin being less frequent. 
Substance P causes excitations of single 
units in the cat spinal dorsal horn; mor-
phine causes depression 5 3. 
Andersen et at•• found that ion-
tophoretic application of met-enkephalin 
reduced the spontaneous firing frequency 
of nociceptive neurons in the trigeminal 
nucleus of decerebrate cats. The 
response evoked by stimulation of the 
tooth pulp was inhibited by enkephalin, 
an effect blocked by iontophoretically-
applied naloxone. Nociceptive neurons 
were strongly excited by substance P. In 
1975 Mayer had pointed out86 the 
simi larities between stimulation-evoked 
and morphine-induced analgesia: both 
are thought to involve an active process 
of pain inhibition rather than merely 
blockade of pain input· both can be 
modified by biogenic a~ines, both are 
blocked by naloxone and both are sub-
ject to tolerance. Chapman reported .. 
that . trans-cutaneous electrical stimula-
tion mduced analgesia during tooth pulp 
stimulation in the majority, but not in 
all subjects; the effect was blocked by 
naloxone. Pomeranz87 at Toronto, 
Seguin88 at Western Ontario and others 
have reported similar analgesic effects 
with electro-acupuncture in animals, but 
others disagree 5 8 • Pomeranz claims70 this 
analgesia is blocked by hypophysectomy, 
which suggests that acupuncture causes 
release of endorphins from the pituitary. 
Modern Chinese methods for inducing 
acupuncture analgesia often involve low-
frequency electrical stimulation of the 
inserted needles. Studies in occidental 
countries have confirmed that pain 
thresholds and pain tolerance in some 
subjects are increased by this procedure. 
As early as 1973 Chang had claimed 7 ' 
that morphine and electro-acupuncture 
analgesia led to a decrease in the rate of 
repetitive discharge of cells in the medial 
hypothalamus. Korf et af1 2 showed that 
cells in the locus coeruleus increased 
their firing rate when noxious stimuli 
were presented; morphine blocked this 
increase and naloxone blocked the effect 
of morphine. In 1975 Mayer 
postulated85 that acupuncture may act 
by releasing a "morphine-like" 
substance which, by a presynaptic effect, 
activates a pain-inhibitory system. 
Naloxone would be expected to reverse 
this analgesic effect and Mayer reported 
preliminary results to support this con-
jecture. Sjolund and Eriksson73 confirm-
ed the blocking action of naloxone in 
electro-acupuncture analgesia and in 
1977 they showed 74 that levels of en-
dorphins increased in the cerebrospinal 
fluid of patients relieved of pain by this 
method. It is of some interest that 
nalaxone does not block analgesia caus-
ed by hypnosis nor general anaesthesia 
with halothane or nitrous oxide. 
In a study of pain thresholds 
measured by electrical stimulation of 
tooth pulp, volunteers received acupunc-
ture, no treatment, or placebo (i.v. 
saline and told it was a powerful 
analgesic)1 5 • Of the 20 subjects showing 
elevations in threshold by acupuncture 
II were given naloxone, i. v., and within 
five minutes their thresholds were in the 
control range. The other 9 were injected 
with saline and their levels remained 
high. Levine et af7 8 studied pain by two 
rating scales after extraction of impacted 
third molars in a randomized, double-
blind trial. Patients were told they might 
receive morphine, placebo or naloxone 
injections at two hours and three hours 
after the start of anaesthesia (diazepam, 
local mepivacain and nitrous oxide.) In 
patients receiving placebo as the first in-
jection and naloxone or placebo one 
hour later the mean pain level increased 
during the hour after the first injection 
and increased even more when naloxone 
was given as the second injection. This 
implies that the surgical procedure led 
to release of endogenous opioids. 
Analysis showed that naloxone enhanced 
the pain ratings much more in placebo 
responders but had no obvious effect on 
placebo nonresponders. Morphine itself 
is known to be more effective in 
placebo reactors than in non reactors 77 • 
Can placebo reactors turn on their en-
dorphin system? Perhaps the time has 
come to envy the placebo reactor rather 
than dismiss him as neurotic . 
Studies of tolerance with these 
substances are few because of their scar-
city and cost, but tolerance does develop 
to f3 -endorphin and met-enkephalin, as 
it does to morphine on repeated injec-
tions and there is cross tolerance be-
tween these substances 46 • Prolonged ad-
ministration followed by naloxone induc-
ed a tyPical "morphine-abstinence" syn-
drome. f3 -endorphin is more potent that 
morphine in suppressing signs of mor-
phine abstinence78 . Animals will self-
administer enkephalins as they do mor-
phine and it is suggested that leu-
enkephalin may play a special role in 
the primary reward pathways involving 
the locus coeruleur , mesencephalic 
reticular formation and lateral 
hypothalamus - the same pathways in 
which electrical self-stimulation is main-
tained by several species, including 
man 2 • 
0 
It is possible that enkephalins and/ or 
f3 -endorphin are involved in the 
development of narcotic dependence. Is 
the drug hunger of the heroin addict 
due to endorphin deficiency? Does ad-
ministration of exogenous narcotic drugs 
decrease endogenous opioid synthesis so 
that the central nervous system becomes 
dependent upon the exogeneous source 
and when its administration is stopped, 
withdrawal effects occur because of defi-
ciency of endogenous opiates? Another 
hypothesis, proposed by Goldstein2 , is 
that a genetic deficiency of endorphin 
production might predispose to opiate 
addiction. Such an idea suggests a new 
way of looking at narcotic addiction; if 
it were a "metabolic disease", then 
society's harsh attitudes might be even 
more inappropriate. Evidence for these 
hypotheses is not yet available. 
Enkephalins and endorphins seem to 
require an intact N-terminal tyrosine to 
combine with the opiate receptor and 
exert their biological effece 9 • In 1978 a 
specific high-affinity enkephalin-
degrading peptidase localized to brain 
membranes was found whose concentra-
tion varied in the brain according to the 
enkephalin levels, its concentration in-
I'm getting worried about Mr. Jones' condition. His payments are 
becoming irregularly irregular. 
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creasing with chronic morphine treat-
ment80. Widespread distribution of pep-
tidases probably accounts for the very 
short biological half-life of enkephalin, 
which is measured in minutes. Synthetic 
analogues of enkephalins which resist 
enzymatic destruction are under in-
vestigation8'. 
As early as 1977 Terenius' group 
mentioned 82 the potential role of en-
dogenous opioids in regulation of pain 
perception and in 1978 Hosobuchi and 
Li announced83 relief of intractable pain 
in three patients by the intraventricular 
injection of 300 microgm human (3 - en-
dorphin. Relief of chronic pain in each 
patient preceded any significant alterna-
tion in acute pain threshold . Both were 
blocked by naloxone. With a larger dose 
relief was profound and lasted about 8 
hr . , but there was no alteration in vital 
signs, neurological function or behaviour 
except that the patients appeared more 
relaxed and cheerful. Last August, Akil 
et a/ showed84 that the analgesia evoked 
by electrical stimulation of periven-
tricular brain sites in 8 patients was ac-
companied by a significant increase in 
enkephalin-like material in the ven-
tricular cerebrospinal fluid . Moreover, 
they, like Terenius86 , found that the 
baseline levels of enkephalins in patients 
with chronic pain were lower than those 
in normal subjects. 
Terenius's group reported that the en-
dorphin levels were very low while pa-
tients were suffering chronic pain; does 
this mean a hypoactive "endorphin 
system" or high consumption of releas-
ed endorphins? They also found85 in pa-
tients classed as having mainly chronic 
organic pain syndromes that the lumbar 
CSF showed significantly lower en-
dorphin activity than that of patients 
whose pain was consid~ed pyschogenic. 
There was a significant correlation bet-
ween CSF endorphin levels and depth of 
psychic depression as reported by the 
patients, but no correlation with anxiety 
or motor retardation . In depressed pa-
tients endorphins may be I 0 times 
higher than in normal subjects88 . 
Terenius' results indicate the importance 
of other actions of the opiates aside 
from pure analgesia in alleviating pain: 
patients feel better than can be at-
tributed simply to their relief from pain. 
It is conceivable that exogenous opiates 
turn off endorphin production and thus 
reduce depression evoked by high levels . 
In a recent study87 of two patients in 
Paris with congenital insensitivity to 
pain but no other neurological deficit, 
the thresholds for a nociceptive flexion 
reflex were markedly elevated, but they 
were greatly reduced within 10 minutes 
after an injection of naloxone . 
One great help in studying the role of 
opiate peptides and receptors is the 
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availability of highly specific antagonists 
like naloxone and naltrexone, but it was 
difficult to assign a very significant role 
for endogenous opiate peptides when 
there had been widespread recognition 
that sudden blockade of the receptors by 
i.v. naloxone had no appreciable effect 
on the organism. Some observations, 
however , suggest that naloxone causes 
hyperalgesia88 and lowers pain tolerance 
in animals8 ', the implication being that 
endogenous opiate peptides may normal-
ly set these thresholds . All of this sug-
gests that an endogenous pain-inhibiting 
system can be called into action whose 
effects can out-last the duration of 
stimulation by many hours. It is not all 
that simple: Akil et a/ 81 found that 
naloxone only partially blocks the 
analgesic effects of electrical stimulation 
and tolerance does not always occur . 
Non-opiate mechanisms must also exist. 
In 1978 Feldberg and Wei reported88 
that injections of morphine, f3 -
endorphin and leu-enkephalin caused an 
increase in heart rate and blood pressure 
when injected into the cerebral ven-
tricles, but opposite effects when in-
jected intracisternally . The car-
diovascular system is considered to be 
very sensitive to the effects of both ex-
ogenous and endogenous opiates and a 
recent study on shock is related to this 
hypotensive action of opioids90 . Rats in-
jected with E. Coli endotoxin had a 
precipitous fall in blood pressure and 
when it had reached 65 mm hg, an in-
jection of saline or naloxone was given . 
Naloxone not only rapidly reversed the 
hypotension, but when given prophylac-
tically , prevented it. This experiment 
may be of great significance not only 
because it suggests that endorphins may 
be involved in the fall of arterial 
pressure in shock, but it also implies 
that narcotic antagonists may have 
therapeutic value in that state. Through 
feedback control it may even provide a 
rationale for the use of corticosteroids. 
Akil reported at the latest meeting of 
the Society for Neuroscience a finding 
with fascinating implications: endorphin 
levels increase markedly in the blood of 
pregnant women. Is this an aid to 
painless natural childbirth? Is it a means 
of keeping a foetus quiet, content and 
not breathing? 
Effects of the opiate peptides and 
their antagonists on the mind are less 
clear than on the brain, but confusion 
does not make them less intriguing. 
When it was discovered that intraven-
tricular (3 -endorphin induced marked 
catatonia in rats and mania and 
hallucinatory behaviour in cats, as 
opiates are known to do, it was con-
sidered that the peptides might be in-
volved in affective disorders. In 1977 
two psychiatrists Kline and Lehmann 
obtained some of Li's precious newly-
synthesized f3 -endorphin and injected it 
into 15 psychiatric patients38 . They 
claimed antipsychotic, antidepressant and 
antianxiety effects9', but the experiment 
was badly-designed, not double blind, 
and the material was even given to some 
patients still taking antipsychotic drugs; 
such was the haste to be first. At best, 
their results are equivocal. Terenius 
reported increased endorphins in the 
CSF of acutely disturbed schizophrenic 
and manic patients and the levels 
decreased during remiSSIOn of the 
psychosis88 • The Swedish investigators; 
reasoning that if endorphin levels do 
correlate with the severity of the 
psychosis, then naloxone should be 
beneficial, found82 that it blocked 
auditory hallucinations in paranoid 
schizophrenics. Others disagreed with 
these results, but in a good double-blind 
crossover study83 naloxone blocked 
hallucinations, decreased anxiety and im-
proved mood. Others showed a decrease 
in euphoria scores, especially in manic 
patients. The implications are that en-
dogenous opiates are involved in some 
psychotic symptomatology; certainly 
these peptides are strategically located 
for modulating events in limbic struc· 
tures . 
Goldstein writes2 that whatever roles 
endorphins have, their interplay with 
nervous and hormonal effects in the 
regulation of behaviour represents the 
perfection of millions of years of evolu· 
tionary adaptation. To swamp endorphin 
receptors everywhere in the body with 
repeated high concentrations of ex-
ogenous opiates such as heroin can only 
upset the natural systems and suggests 
even greater caution in prolonged use of 
antagonists and the non-medical use of 
narcotic analgesics. 
The very existence in the body of pep-
tides with opiate activity raises the ques-
tion of their true physiological role 
because it seems that all mammals have 
them. It is everi possible that their 
opiate-like activity is misleading us48 • 
Results of the studies I have summariz-
ed are very new, very exciting, creative, 
and full of ·promise, but although all 
kinds of wonderful and ingenious sug-
gestions are being made in the literature 
about novel neurotransmission, blocking 
acute pain, suppressing and modulating 
chronic pain, involvement in stress and 
shoe)<, reversing schizophrenic symp· 
toms, relieving psychic depression and 
anxiety, explaining drug addiction, 
acupuncture and placebo responses, the 
real ex~erts like Kosterlitz, Hughes and 
Goldstem warn us84 that we still cannot 
assign a role to the enkephalins. We do 
~ot even know for sure what target 
tissues they act upon and it is not yet 
proper . to talk about an endorphinergic 
anal~esJc system which mobilizes opiate 
peptldes to cure our ills. 
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Antibiotic Update 
Over the past five years, several new an-
timicrobial agents have been introduced. In 
this article, I will brieny review what I con-
sider is their role in the therapeuti cs of in -
fectiou s di seases by comparing them with 
older, established antibiotics. Only signifi-
cant differences or similarities will be em-
phasized and no detailed pharmaco logic o r 
microbiologic review of these drugs will be 
attempted . 
Penicillins 
Two relatively new penicillin ana logue 
are currently available. The first, amox-
icillin (AmoxiJR, PenamoxR, NovamoxinR, 
PolymoxR, AmoxicanR), is now we ll 
established and has superceded o ral am-
picillin to a large extent. Its spectru m of ac-
tivity is vi rtually identical to that of am-
picillin but it possesses marked phar-
macokinetic advantages including better 
absorption (even in the presence of food) 
and higher blood a nd urine levels. As a 
result of this, the indi vidual doses of amox-
icillin required are only 500Jo those of am-
picillin and the drug may be given every 
eight rather than every six hours. There ap-
pears to be concomitantl y less diarrhea, a 
common si de effect of ampicillin, 
associated with its use also . However, eve n 
with the dose reduction, the drug is still 
somewhat more expensive than oral am-
picillin and this must be weighed against its 
obvious advantages. At the present time, 
moreover , ampicillin is the only drug 
available for parenteral (intramuscular or 
intravenous) use. 
Ticarcillin (TicarR) is the newest penicillin 
analogue with an antibacterial spectrum 
and pharmacokinetics very s imilar to that 
of carbenicillin. It is available only in a 
parenteral form and is therefore rest ricted 
to hospital use only. It is more active 
against most s train s of Pseudomonas 
aeruginosa than carbenicillin and therefore 
the daily dose required in pseudomonas in-
fections is approximately 600Jo that of 
carbenicillin (for example, 18G vs . JOG). 
This results in a substantially lower sodium 
load for patients on tica rcillin (approx-
imately 90 milliequivalents vs. 150 milli -
equivalents of sodium per day with 
carbenicillin) and may also cause less 
platelet dysfunction and bleeding problems 
which large doses of carbenicillin have been 
shown to produce. Despite the lower dose, 
however, there appears to be no significant 
cost advantage in using ticarcillin rather 
than carbenicillin, at the present time . 
For se ri o us sys temic Pseudomonas 
aeruginosa infections, eit her tica rci llin or 
ca rbenicillin is ge nera ll y used in combina-
ti on with ge nt a mici n o r tobramycin since a n 
ami noglycoside combined with these drugs 
usually produces a sy nergi stic antibac terial 
effec t. Ticarcillin o r ca rbenicillin alone may 
also be used in th e treatment of infections 
caused by ot her G ram negative o rgani sms 
resis tant to a mpi ci llin , o r in patients in 
whom an aminoglycoside an tibi otic is co n-
traindicated . 
Cephalosporins 
The cep ha losporins a re excell ent a lter-
native bactericidal drug for patient s 
a ll ergic to the penicillins (cross hyperse n-
sitivity between these tw o classes of drugs 
being on ly 5 to IO OJo). Their a ntibacter ial 
spectrum is rather broad a nd includes all 
staphylococc i (including penicillin resista nt 
s trains) and seve ral Gram negative 
organisms including klebsiella. One signifi -
can t drawback is their inabi lit y to cross the 
blood brain barrier in therapeutic concen-
trations and therefore they should not be 
used in the treatment of meningiti s . 
The most recent cephalosporin prepara-
tion introduced is cefamandole (Mandol R) 
which differs from th e older drugs such as 
cephalothin (KeninR) in having a broader 
Gram negative pectrum. Another which 
will be introduced sho rtl y is cefox itin (ac-
tua ll y a cep ha mycin derivative) which is 
also active agai ns t many s train s of 
Bacteroides jragilis, a n int es tina l anae robe 
which is genera ll y resistant to the o lder 
cephalosporins. 
Cefazolin (AncefR, KefzoJ R), whic h has 
been available for approximately five years, 
is sti ll distinctive among the cephalosporins 
in possessing very favo urable phar-
macoki netic properties with high serum 
levels and a long half-life. This results in a 
lower daily dose (I G given every 8 hours 
I.M . or I.V ., for most patients) than the 
other cephalosporins cur rently avai lable 
and has become the cephalosporin recom-
mended at our hospital. Since cefazolin is 
not available as an oral preparation, either 
cep hale xin (KeflexR, CeporexR) or 
cephradine (VelocefR) can be used . 
Even with the availability of newer 
cephalosporins, cefazolin will likely remain 
the drug of choice in most situations. 
However, for specific serious infections 
such as endocarditis, it may be better to 
refine our therapy with the cepha lospori ns, 
choosing a particular one for Gram positive 
by Dr. E. D. Ralph 
infections and a different one for Gram 
negative infections . 
Aminoglycosides 
Tobramycin (NebcinR) and amikacin 
(AmikinR) are the most recently introduced 
aminoglycoside drugs. Tobramycin is very 
similar to gentamicin in its spectrum of ac-
tivit y against Gram negative organisms, ex-
cept that it is more active against st rains of 
Pseudomonas aeruginosa but less active 
against certain less common Gram negative 
organisms such as serratia . It appears to be 
less nephro- and ototoxic than gentamicin 
in animal models but no convincing 
evidence has been prese nted that it is 
significantly less toxic in the human . Both 
ge nta micin and tobramycin are prescribed 
similarl y with modifications for impaired 
renal function and therefore the BUN and 
serum creat inine are followed closely while 
patients are on these drugs. If there is any 
co ncern about ototoxicity, audiometry can 
be performed periodically since the loss of 
high-tone frequency perception may 
precede obvious vestibul ar or auditory tox-
icity . Peak a nd trough serum levels of the 
drugs are also frequently measured as well 
to ensure therapeutic but not toxic levels 
since th e therapeutic index in these drugs is 
quite low. Either gentamicin or tobramycin 
is used currentl y as the aminoglycoside of 
choi ce in most hospitals. 
Amikacin, the newest a minogl ycos ide 
available, is closely related to kanamycin, 
an an tibiotic which was su perceded to a 
large extent by gentamicin in the late 
1960's. Amikacin has a spectrum of activity 
similar to gentamicin and tobramycin ex-
cept that it is often active against organisms 
which are resistant to these drugs. The dose 
and do sage interval are simi lar to 
kanamycin with modifications made for im-
paired renal function . Amikacin is an ex-
cellent drug to have in reserve for gen-
tamicin or tobramycin resistant strains, but 
its use fulness in this respect may be curtail-
ed if it is used as a first-line drug. 
Trimethoprim-sulfamethoxazole 
(cotrimoxazole) 
Trimethoprim-sulfamethoxazole (Sep-
traR, BactrimR) represents the product of 
basic pharmacologic research to develop a 
sy nergistic combination of two an-
timicrobials. Whereas sulfonamides have 
been available for many years, their spec-
trum and antibacterial effects have been 
enhanced greatly with the addition of 
trimethoprim. The fixed combination of 
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these two antimicrobials has a broad spec-
trum of activity against both Gram positive 
and negative organisms (except Pseudomas 
aeruginosa) and has been used primarily in 
the treatment of upper a nd lower 
respiratory tract and urinary tract infec-
tions. It may be especially useful in recur-
rent or relapsing infections caused by resis-
tant Gram negati ve o rgani sms . Unfor-
tunately, it is likely that some of the older 
antibiotics have been neglected wit hout 
good cause as a result of the widespread use 
of cotrimoxazole. In general , cotrimoxazole 
should be considered in most infections as a 
second-line drug after such established an-
tibiotics as the penicillins, cephalosporins, 
sul fo namides alone , erythromycin or 
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" A calling or vocation requm ng specialized knowledge 
and intensive preparation." 
The members of the Ontario Medical Association know 
that in today's world , specialized scientific knowledge is 
not all there is to medicine. A wide range o f issues face 
physicians - from the economic squeeze in healt h care 
and the intri cacies of running a practice that's a lso ~ 
busines~ , to dealing with political pressures and keeping 
pace w1th a fast-changing society . To yo u , as a student , 
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the O.M .A . offers part of your intensive preparation for 
the profession of medicine . 
For information on joining the Ontario Medical Associa-
tion, si mpl y write Anne Todd, Supervisor of Membership 
O .M .A., 240 St. George Street, Toronto M5R 2P4· 0 ; pho~e 925-3264 (in Toronto), 1-800-261 -7215 (toll~free 
outs1de Toronto) 
Joining is onl y your fi rst step in partici pation . 
On the Competitive Urge 
To have the urge might be said to im-
ply potential or hopeful utilization of 
energy. In the case of the archetypal 
medical cadre, normal libidinous drives 
are sublimated into pathological com-
petitive drives . In other words , being on 
top of your classmate refers to academic 
superiority rather than reproductive 
alignment. 
The medical student has rested his 
self-esteem in pre-med years on the 
ability to thrash to an intellectual pulp 
his pre-med rivals . Once the cycle of be-
ing better is begun and reinforced, the 
student is incurable. However, both 
nature and marks in medical school 
have devious ways. 
Med students employ a variety of 
ways to deal with this urge . It 's not 
quite as simple as a cold shower 
however. Like ego defense mechanisms 
in psychiatry, these urges can be dealt 
with in more advanced and complicated 
ways or by more primitive and simple 
ways . Probably the most primitive way 
you can deal with your " urge" 
(competitive) is by doing that much 
more study and work than your peers in 
order to appear intellectually superior. 
Surgeons are known to work hard . The 
only explanation here, I gather , is that 
this way of dealing with your "urge" 
doesn't work so well . Another primitive 
way of handling the "competitive urge" 
is by using denial. Eg: a pre-exam con-
versation between students, 
"I didn't study at all for this exam." 
"I studied even less!" 
"Impossible, I went to the movies 
last night." 
"That's nothing! I played gin rummy 
all night and drank beer . '' 
"So I lost all my ICC notes, Har-
rison's, Merck Manual and Guyton 
on the horse races last night." 
"That's nothing! I never took notes, 
bought the textbooks, or attended 
lectures." 
etc., etc., etc ., 
A more advanced means of coping 
with competitive urge is by asking pro-
fessors seemingly extremely difficult 
questions during lecture periods. This 
idea here is basically, 
"Wow, that guy must ktt0~ a lot if 
he's asking questions about this stuff. 
Some examples of questions to ask that 
will make you appear bright: 
"What percentage of people with 
loose teeth have Burkitt 's lymphoma 
of the jaw?" 
The person who asked this question 
subsequently had radiographs of his 
mandible taken when his classmates 
knocked his teeth out for asking such a 
stupid question. 
Or: 
" What is the incidence of mice, who 
have had their foot pads injected 
with measles antibody, who have an 
IQ of greater than 50?" 
Just as a child becomes an adult , a 
medical student becomes a physician. In 
fact an old saying explains this rather 
well, "A med student is simply a doctor 
with his brains kicked out." Anyway, a 
by Doug Zochodne 
physician, like a student, retains his 
competitive urge . 
If he is a professor , his underlings 
must be able to deal with this. How to 
handle it? Always appear to be working 
harder for solutions than the professor 
but appear much more stupid despite 
this work. If the professor blunders, 
take full responsibility (this may not be 
optional). Ask questions for which the 
professor should know the answer to. 
This may backfire if the professor is 
unusually limited . 
In summary , the medical student must 
really learn to be like the student coun-
cil candidate who demanded , "Better 
food , more booze , more broads!" in-
stead of "More Harrison's, more ICC, 
more exams!" 
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Contraception: 
The Past, The Present, The Future 
The past two decades have witnessed 
the greatest changes in the field of con-
ception control, not only from the 
standpoint of increased numbers of 
available contraceptive products , but 
more important in the attitudes of both 
the medical and lay public to the basic 
concept of "man's right to adequately 
space and limit the number of his pro-
geny, i.e., family planning". 
The following is a brief review of the 
history of contraception which has 
brought us to our current "state of the 
art". Consideration of future possi-
bilities in conception control are also 
presented . This presentation is not 
meant, by any means, to be a com-
prehensive in-depth review, but rather to 
present the highlights of the past, pre-
sent and future of contraception. 
THE PAST 
Contraception is not a new concept. 
Dating back to ancient times, women 
have attempted to prevent conception by 
various methods, some of which seem 
rather strange or bizarre in the light of 
our current knowledge of the reproduc-
tive process. Still, these • attempts were 
often the only means available. 
Incantations, physical gyrations and 
the insertion of various potions into the 
vagina (many of which were extremely 
noxious to tissues and resulted in per-
manent scarring and stenosis) were 
employed . 
The condom, originally produced as a 
membrane from animal intestines, was 
developed as a means of protection 
against venereal disease , a problem 
which has plagued man throughout cen-
turies . Its artifertility effect was a bonus 
to the consumer . 
During the pre-Christian era, caravan 
leaders were known to place pebbles in-
to the uteri of their camels in order to 
prevent them from becoming pregnant 
during their long travels across the 
desert. 
It was not until the elucidation of the 
steps in the reproductive process of both 
the male and the female, that contracep-
tive technique£ were developed which 
would act at one or several sites along 
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the complex pathway from conception 
to implantation. 
THE PRESENT 
I. Pseudo-Contraceptive Techniques 
Coitus interruptus, or withdrawal and 
douching may have played a role in 
contraception when few better techniques 
were available, but in this age has no 
place, and if anything, is mentioned 
here only to be condemned. 
II. Ovulation Timing Techniques 
Periodic abstinence or rhythm , "the 
natural contraceptive method", has sur-
vived the centuries because it does 
nothing artificial to the body for its ef-
fectiveness, and thus offends no 
religious doctrines . Its inadequacy , 
however , lies in the fact that "all 
women are not created equal" at least 
insofar as the regularity of their 
menstrual cycles and timing of ovulation 
are concerned . Modern refinements in 
this technique based upon current 
knowledge of the menstrual cycle have 
somewhat improved upon the efficacy of 
this method . These include basal body 
temperature charting, assessment of 
vaginal pH and cervical mucous changes 
(Billing's method) which act as in-
dicators of impending ovulation. 
III. Spermicides 
Spermicidal agents delivered in the 
form of gels, creams and foams which 
act as the vehicles, have survived the 
test of time. The major substance 
employed as the spermicide, regardless 
of the vehicle, is nonoxynol-9 . Recent 
claims by the manufacturer of one J:lrod-
uct produced in the form of a vaginal 
suppository which effervesces upon in-
sertion into the vagina, is an effec-
tiveness rate approaching that of the 
oral contraceptives. This statement is far 
from true, and in fact, is similar to the 
failure rate (pregnancy rate) associated 
with the other spermicides. 
Insertion of these agents into the 
vagina should, for the most effective 
results, be no longer than 30 minutes 
prior to coitus, and a new application 
should preferably be employed with each 
subsequent act of intercourse. 
by A. Albert Yuzpe, MD. 
IV. Barrier Methods 
The condom and the diaphragm too 
have survived the modern contraceptive 
evolution with little refinement other 
than the basic materials from which 
they are manufactured. 
The major refinements in the condom 
have been in the production of a thinner 
membrane in order to overcome one of 
the major objections of the male con-
sumer , i.e., loss of sensation. However, 
this has resulted in an increased in-
cidence of rupture of the condoms with 
resultant leakage of the sperm. Further-
more, as was pointed out earlier in the 
case of women, "all are not created 
equally" similarly "not all men are 
created equally". In some cases the con-
dom may slip off, generally after 
ejaculation when the erection is lost, 
again with resultant leakage of sperm. 
Perhaps the major problem associated 
with the condom is the fact that it is 
often applied too late. If intromission 
occurs during the stage of sexual 
arousal, and prior to condom applica-
tion, seminal fluid containing sperm 
may be released into the vagina resulting 
in pregnancy . 
Refinement in the spring or coil of 
the diaphragm rim has made proper in-
sertion easier, as have the accompanying 
inserters. A spermicidal gel must always 
be used in conjunction with the 
diaphragm and is applied around the 
rim of the device prior to insertion. 
Furthermore, the device should be left 
in place for eight hours following coitus 
and then removed, cleaned, inspected 
and stored. 
V. Mechanical Contraception 
I. Diaphragm 
2. Intrauterine Devices 
At the beginning of the twentieth cen-
tury, Ota in Japan experimented with 
intrauterine rings of silkworm gut and 
later Graafenberg in Germany, devel-
oped the intrauterine ring composed of 
German silver. Its efficacy later proved 
to be largely due to the high content of 
copper in this metal alloy. 
The "plastic revolution" resulted in 
the development of the current first 
generation, or non-medicated, IUD's. 
These devices were composed of 
substances such as polyethylene and 
were designed in various shapes in order 
to achieve less distortion of the uterine 
cavity. Their effectiveness depended 
largely upon their size since the greatest 
contraceptive efficacy was obtained 
when a large surface area of the device 
was in contact with the endometrium. 
The discovery that metal such as cop-
per could enhance the antifertility effect 
of the non-medicated devices by a 
regular and sustained release of copper 
ions into the endometrium enabled the 
refinement of the plastic matrix. The 
size was then able to be reduced without 
sacrificing contraceptive effectiveness. 
Further refinements occurred in the 
IUD with the development of a mem-
brane which had the property of zero 
order release . This led to the production 
of a device in which a steriod such as 
progesterone could be encased and 
released at a predictable daily rate . The 
result was the production of an atrophic 
endometrium unreceptive to implantation 
of the fertilized ovum. 
Our current understanding of the 
mechanism by which the IUD imparts 
its antifertility effect is incomplete. 
Theories of increased tubal and uterine 
motility producing rapid transit and 
subsequent expulsion of the ovum are 
no longer accepted. An endometrial in-
flammatory response due to the presence 
of an intrauterine foreign body occurs. 
This leukocytosis as well as alteration in 
various enzymes such as carbonic 
anhydrase seem to produce the antifertility 
effect which is further enhanced by the 
direct endometrial effects of the 
progesterone or copper ions . 
The evolution from the non-medicated 
to the new medicated devices in the past 
ten years seems to have succeeded in 
providing fairly effective although not 
absolute contraception with reasonably 
acceptable side effects . 
VI. Steroidal Contraceptive 
Pharmacologic developments in steroid 
synthesis and extensive animal ex-
perimentation have provided various 
forms of steroidal contraception in-
cluding oral, injectible and subcutaneous 
implants. These agents, primarily the 
oral steroids, have and are providing ap-
proximately 50 million women through-
out the world with effective ongoing 
contraception. 
No single class or group of drugs has 
ever been researched, scrutinized and 
criticized more extensively than oral con-
traceptives. 
Originally, levels of 100 micrograms 
of estrogen per tablet were felt necessary 
to produce the desired antiovulatory ef-
fect. With the demonstration of the 
relationship between estrogen dosage and 
the more serious side effects such as 
thromboembolic phenomena, attention 
was focused at lowering the estrogen 
dosage without sacrificing contraceptive 
efficacy. 
In the attempt to more closely 
simulate the normal hormonal pattern of 
the menstrual cycle, the sequential oral 
contraceptives were formulated. Estrogen 
alone at doses of 75 to 100 micrograms 
per day were administered for the first 
eleven days of therapy, followed by the 
addition of a progestin combined with 
the estrogen in the last ten days. 
Heavier menses and a significant 
breakthrough ovulation rate with resul-
tant increased numbers of pregnancies 
were a problem. Furthermore, the 
association between such formulation s 
and the development of endometrial 
hyperplasia and even endometrial car-
cinoma resulted in their withdrawal as 
oral contraceptives. 
Formulations containing progestin on-
ly were developed in an attempt to 
totally avoid the use of estrogen with its 
potential side effects. Poor cycle control 
(irregular bleeding) and a higher 
pregnancy rate have contributed to a 
limited use of this type of medication . 
Its major value today is in the patient 
where the use of estrogen is contrain-
dicated and yet an oral contraceptive is 
desirable , e.g., the lactating patient and 
those with a history of estrogen depen-
dent side effects or disease. 
Synthesis of more potent progestins 
has resulted in the production of oral 
contraceptives containing 50 micrograms 
and more recently , even 35, 30 and 20 
micrograms of estrogen. For many years 
the 50 microgram pills were popular and 
overcame many of the estrogen-related 
side effects. In the last few years the 
35, 30 and 20 microgram formulations 
have increased tremendously in populari-
ty. However, at the 20 microgram level, 
a greater incidence of breakthrough 
bleeding and slight decrease in con-
traceptive efficacy has resulted in limited 
use of this formulation. For this reason, 
the majority of oral contraceptives 
utilized at the sub-50 microgram dosage 
level are the 30 and 35 microgram ones. 
Although no hard scientific data is 
available to support a decreased in-
cidence of side effects with these lower 
dosage formulations, it appears that it is 
still wiser on the part of the physician 
to choose these products as a first 
choice. 
Subcutaneous implants of long acting 
estrogen pellets have had limited use , 
but with good contraceptive effect. 
Injectible long acting progestins such 
as medroxy-progesterone acetate can be 
used for long term ovulation suppres-
sion, but may in fact produce excessive 
suppression beyond the desired end 
point. Amenorrhea results with its use 
and at the same time irregular spotting 
often occurs. The latter often decreases 
acceptability of this potent progestational 
agent. Furthermore, the association 
between this compound and the 
development of breast tumors in female 
beagle dogs has resulted in its withdrawal 
for use as a contraceptive agent, although 
no association has been demonstrated in 
humans . 
Other long acting estrogen compounds 
have been used as injectible contraceptive 
agents, but again with only limited 
acceptability. 
In summary, continuous reevaluation 
has enabled the dosage of the steroids, both 
estrogen and progestin, to be reduced to a 
minimum without sacrificing contraceptive 
efficacy to any great extent, and in some 
cases has resulted in a lower incidence of 
untoward effects. When well tolerated and 
properly taken these preparations provide 
almost fool proof contraception for their 
users. 
VII. Sterilization 
In recent years more and more 
couples are turning to sterilization as a 
means of permanent contraception. 
More readily available and simple 
techniques have been developed which 
have become more universally accessible. 
Organizations such as the Association 
for Voluntary Sterilization with its 
worldwide exposure has done much to 
promote education and availability of 
sterilization techniques throughout the 
world in both developed and lesser 
developed countries. Sterilization should 
always be considered a permanent pro-
cedure. Couples should never be 
counselled on the basis that a steriliza-
tion procedure is readily and universally 
reversible . Even in the light of today's 
surgical skills such as tubal micro-
surgery, no single procedure can boast 
lOOo/o efficacy and 100% simple rever-
sibili ty (which is measured by full term 
intrauterine pregnancy) . 
Once the decision is made to undergo 
sterilization, surgical procedures are 
available either for the male or the 
female. Further counselling has been 
necessary so that the choice between the 
male and female procedure can be made 
by an informed and knowledgeable cou-
ple. 
Male Sterilization 
Vasectomy: This procedure involves 
surgical occlusion, with or without resec-
tion, of a segment of the vas deferens. 
The advantages to this form of steriliza-
tion as opposed to female sterilization 
include: 
1. Relatively simple surgical technique 
to master 
2. An out-patient, office or clinic 
procedure 
3. May be performed under local 
anesthesia 
4. A low failure rate . 
The disadvantages include: 
1. The presence of an accessory vas 
may result in failure. 
2. Follow-up semen analysis is 
necessary six to eight weeks 
following the procedure to ensure 
azospermia. 
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3. Possible psychosexual compli-
cations if the male is not totally 
convinced and motivated to have 
the procedure-e.g. impotence . 
Recent, but as yet preliminary, animal 
studies have shown an increased in-
cidence in the development of premature 
atherosclerotic changes in animals 
undergoing vasectomy as compared to 
controls. This is premature and un-
published data and requires a great deal 
of further scientific investigation before 
any definite conclusions can be drawn. 
Female Sterilization 
Tubal ligation is generally used to 
refer to any form of tubal occlusion 
carried out surgically with the aim of 
producing permanent sterility. However, 
recent experiences in the courts suggests 
that a differentiation or distinction 
should be made between the terms tubal 
ligation and tubal occlusion if for no 
other reason than to confirm the pa-
tient's informed consent. 
1. Hysterectomy: Although hysterectomy 
can certainly achieve sterilization, it is 
reserved by most physicians for those 
women requesting sterilization who have 
associated gynecologic pathology, e.g., 
abnormal Pap Smear, menstrual 
dysfunction , endometriosis, PID, and 
uterine prolapse. 
Caesarian hysterectomy is also ad-
vocated by some but the morbidity and 
mortality rates are too high to consider 
such a combined procedure except under 
exceptional circumstances. 
2. Tubal Sterilization: There are three 
major variables in approaching tubal 
sterilization. These include the timing of 
the procedure in relation to pregnancy, 
the route of approach to the fallopian 
tubes and finally the method of tubal 
occlusion. • 
(i) Timing 
Post partum - three to four 
days following delivery Interim 
(ii) Route of Approach 
Abdominal 
-Conventional laparotomy 
-Mini-laparotomy 
Vaginal 
-anterior or posterior col-
potomy 
Endoscopic 
-abdominal-laparoscopy 
-vaginal-culdoscopy 
-transuterine-hysteroscopy 
(iii) Method of Occlusion 
1. Complete resection of both 
fallopian tubes-total salpingectomy. 
2. Partial resection of tubes-
fimbriectomy (Kroener technique) 
3. Mid-segment resection (Pomeroy 
technique) 
4. Others - Uchida, Aldrich, Irving 
etc. 
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5. Electrocoagulation 
-burn only 
- burn and transect 
- burn and resect 
6. Mechanical occlusion 
- silastic band (Falope ring) 
-clip (Hulka clip) 
The two most commonly employed 
approaches to interim sterilization are 
laparoscopy and mini-laparotomy. Any 
of the occlusive techniques may be 
employed with the latter approach, 
whereas electrocoagulation or one of the 
mechanical occlusive techniques is 
employed with laparoscopic sterilization. 
Failure rates vary with different pro-
cedures from 1-7/1000. It appears that 
these rates are highest with post partum 
procedures or when performed con-
comitantly with Caesarian section. 
Sterilization Reversal 
The current rate of 1-20Jo of previous-
ly sterilized women requesting reversal 
of the procedure appears to point out 
two important factors. The first, is the 
necessity for more in depth counselling 
of the patient, or preferably the couple, 
so that they fully understand the im-
plications of their decision. Secondly, 
some mechanism, until now non- exis-
tent, for selecting those individuals who 
will be the ones most likely to return re-
questing reversal is necessary. It is in-
teresting to note that it does not appear 
to be the young nulliparous woman or 
the one of low parity who requests 
reversal. Once such women as these 
make the decision to have a sterilization 
they appear to be among the most 
highly motivated to maintain their 
freedom from fertility for various 
reasons. It has been our personal ex-
perience that it is the patient with two 
or three children who is her late twen-
ties and early thirties who requests the 
procedure. 
At present, with the state of the art 
as it exists, reversal of sterilization re-
quires a full laparotomy , a technically 
exacting (often microsurgical) procedure 
of two to five hours duration, five to 
seven days of post-operative hospitaliza-
tion, a variable post-operative recuper-
ative period at home, and a success 
rate, at best, of 65%. Furthermore, suc-
cess can only be measured in full term 
intrauterine pregnancies since post 
operative tubal patency alone does not 
imply success of the procedure. As well 
the incidence of ectopic (tubal) gestatio~ 
is increased up to five times following 
tubal reanastomosis, i.e., reversal of 
sterilization. 
For - these reasons, reversal of tubal 
sterilization should not be taken lightly 
nor encouraged by the physician. Most 
of all, couples should never be coerced 
into undergoing a sterilization procedure 
on the basis of ease of reversibility. 
It is beyond the scope of this discus-
sion to deal with other very important 
and pressing issues in the realm of con-
traceptive sterilization, namely the men-
tally retarded patient and the physically 
handicapped minor. Suffice it to say, 
that there has been enough concern in 
these areas, that specific committees 
have been established to evaluate current 
practice and establish certain guidelines. 
Vasectomy reversals are also being re-
quested. Although reanastomoses are 
most often possible, restoration of fer-
tility is by no means guaranteed. 
VIII. Menstrual Extraction 
Menstrual extraction or regulation, is 
a technique which has recently come in-
to vogue in some countries. In this 
minor office procedure, the uterine cavi-
ty of women whose menstrual periods 
are delayed for one or two days, is 
aspirated with a simple form of suction 
apparatus. Commercially available 
pregnancy tests at their present level of 
sensitivity would generally not detect a 
pregnancy in such cases. As a result, 
this procedure may in fact be an early 
abortive procedure and thus subject to 
all the criticisms of abortion. When us-
ed, it should be as a final resort and 
not a means of supplanting acceptable 
contraceptive methods. 
IX. Abortion 
Abortion is mentioned at this point 
only for the sake of being complete. In 
some countries this procedure functions 
as an acceptable and sometimes the only 
contraceptive modality. However, in our 
society in North America, this author 
condemns the use of abortion as an ac-
ceptable alternative to ongoing con-
traception. Most physicians dealing with 
contraceptive counselling would agree 
that the education of the public regard-
ing contraception, promotion of ac-
cessibility and a genuine sympathetic 
rapport with the patient is far more 
desirable. 
X. Post-coital Contraception 
This form of contraception has its 
major value as an emergency measure to 
prevent unwanted pregnancy resulting 
from a single unprotected coital ex-
posure, e.g. rape. Estrogens (synthetic, 
natural and conjugated) have been 
employed successfully in high doses to 
prevent implantation (interception). 
Diethyl-stilbestrol (50 mg. daily for five 
days) has been used most extensively for 
this purpose with a reported failure rate 
of 0.0 to 2.4%. Ethinyl estradiol (2- 5 
mg. daily for 5 days) and a conjugated 
estrogen (30 mg. daily for 6 days) have 
also been employed with failure rates of 
0.0 - 1.1 and 0.0 - 1.5% respectively 
obtained . 
The major disadvantage to such 
therapy is the production of nausea and 
vomiting. This unpleasant side-effect fre· 
que~tly. resu_Its in negative patient 
m?tivatJOn With cessation of treatment 
pnor to completion of the entire course 
of therapy. 
Progestins alone have also been 
evaluated as post-coital agents but 
primarily as an ongoing method. In 
such cases, the progestin is ingested 
after each coital exposure. Poor cycle 
control as well as method failures have 
resulted in a waning of the interest in 
this regimen. 
A combination of ethinyl-estradiol and 
dl-norgestryl has recently been evaluated 
for similar purposes and shows promis-
ing results both from the standpoint of 
efficacy as well as a decrease in side ef-
fects. 
To date, however, no fool-proof, 
oral, post-coital contraceptive agent has 
been developed. 
Copper-containing intrauterine devices 
have been reported to be effective as 
post-coital contraceptive agents if in-
serted within five days of unprotected 
coital exposure. The data are still 
limited to make any definitive comments 
as to the efficacy of such a technique. 
Pregnancy (Failure) Rates 
A major factor determining the 
ultimate pregnancy or failure rate with 
any reversible contraceptive method is 
patient motivation. The various barrier, 
chemical, ovulation timing and oral con-
traceptive methods require motivation 
for their use with every coital exposure. 
Thus, improper use or total failure to 
utilize the method on any occasion 
results in higher failure rates. Only the 
intrauterine device requires no ongoing 
motivation for its effectiveness, beyond 
a single initial motivation to have the 
device inserted. 
The second consideration is patient 
tolerance for side effects and the 
nuisance aspect of the method. Since 
lack of tolerance for nuisance side ef-
fects results secondarily in decrease or 
loss of motivation, subsequent pregnan-
cy becomes a reality. 
These two factors must be considered 
when evaluating the effectiveness of any 
contraceptive modality which requires 
continuing motivation. Thus, method 
failures should be considered separately 
from patient failures. 
Sterilization failures, however, have 
the variables of method failure as well 
as, surgical error to contend with. In-
advertent ligation of structures other 
than the fallopian tubes or inadequate 
occlusion do occur much more frequent-
ly than one would wish to acknowledge. 
In such cases only visualization of the 
tubes in case of a failed sterilization can 
establish whether the failure was a 
method-related one or a surgical error. 
Failure rates for the methods discuss-
ed in this section are demonstrated in 
Fig. l. They appear from their 
magnitude in several instances to reflect 
the influence of patient failure superim-
posed upon method failure. 
In order to increase consumer motiva-
tion attractive packaging has been 
employed by manufacturers. In the case 
of condoms, the colours of the rainbow 
and exotic names have been utilized to 
increase the interest of the male or even 
his sexual partner. 
Combinations of methods such as the 
condom or IUD and a spermicide in 
motivated individuals has helped to fur-
ther decrease failure rates to very accep-
table or at least tolerable levels. 
THE FUTURE 
The future of contraceptive evolution 
is unlimited. However, when one con-
siders any research dealing with new 
contraceptive technology, its worldwide 
applicability becomes an extremely im-
portant factor . Simple techniques which 
can be self administered or delivered 
under the supervision of paramedical 
personnel, which are of low cost and 
have minimal side effects are mandatory 
considerations. For example, a method 
which produces a high incidence of ir-
regular bleeding would be unacceptable 
to certain cultures, especially those 
where menstruation precludes the par-
ticipation of the female in daily ac-
tivities and perhaps even results in her 
banishment to a "menstrual hut". 
As far as the male is concerned, some 
cultures equate male fertility with virility 
and leadership. Thus male contraception 
would not be an acceptable alternative 
in such cases. 
When one considers the costs 
associated with the development of new 
contraceptive technology as well as the 
ever increasing restrictions established by 
governmental drug regulatory agencies, 
it appears easier to understand the reluc-
tance on the part of private industry to 
pursue large scale investigations . 
Political events such as the establish-
ment of cultural and trade exchange 
with China has, among other things, ex-
posed the western world to Chinese con-
traceptive technology. Naturally occur-
ring substances such as Gossypol, a 
plant derivative, as well as other herbal 
antifertility substances are currently be-
ing investigated. Similar herbal extracts 
employed as contraceptive agents in 
other countries are also being evaluated. 
Male Contraception 
Reversible methods of male contracep-
tion are currently being evaluated. 
However , no major breakthrough ap-
pears to be on the horizon. 
Suppression of spermatogenesis has 
been achieved with various chemical 
substances, both natural as well as syn-
thetic. The major problem encountered 
with such methods involves either a con-
comitant suppression of normal steroid-
ogenesis or failure of reversal of sper-
matogenesis once the medication is 
withdrawn. 
However, the search for a male con-
traceptive agent or "male pill" con-
tinues. The question as to how the 
female partner would accept or rely 
upon a positive response to her ques-
tion, "John, did you take your pill to-
day?" is still open to question and fur-
ther clouds the issue. The fact still re-
mains that it is the woman who 
becomes pregnant and suffers greatest 
from an unwanted pregnancy and thus , 
in many cases by choice, the burden of 
contraception has fallen upon her 
shoulders . 
Female Contraception 
l . Barriers: Medical reporting in the 
various media, at times misinterpreted 
or taken out of context, has raised con-
siderable doubts and fears in the minds 
of many women with relation to the 
oral contraceptives and the intrauterine 
device. This has led to the populariza-
tion of research in barrier methods . One 
of the more promising of the methods 
appears to be the intravaginal sponge 
composed of polyethylene or collagen. 
Studies to date, however , suggest that it 
is necessary to incorporate a spermicidal 
agent into the sponges in order to 
achieve acceptable antifertility rates. The 
sponge is left in the vagina for several 
days and removed by the patient, 
cleansed and reinserted . Unpleasant 
odours and as yet unproven efficacy 
rates have prevented their large scale use 
until now. 
2. Mechanical devices: 
(a) The intracervical device (lCD) is a 
small structure composed of a plastic 
polymer which is inserted into the cer-
vical canal as opposed to the uterine 
cavity. If this were possible, then the 
device could be envisaged as a carrier 
vehicle for delivery of various 
substances to the cervix, vagina and 
even the uterine cavity and thus affect 
conception, e.g. , spermicide, steroids, 
immunologic agents etc . 
Expulsion, cramping, pain and cer-
vical perforation have been until now , 
the major stumbling blocks in the pur-
suit of this avenue of contraception. 
(b) New configurations of intrauterine 
devices or old shapes covered by metals 
or encapsulating synthetic steroids for 
sustained release over long periods of 
time are also being evaluated. Similar 
problems as with existing intrauterine 
devices appear to plague these new 
developments, e.g., CUT 220, Multiload, 
long acting progesterone releasing 
device. 
3. Steroidal contraception: Delivery 
systems as opposed to new steroid syn-
thesis appear to be the major 
developments being evaluated . 
(a) Vaginal Rings: Zero order steroid 
release can be obtained from a 
polymeric ring much the same way that 
progesterone is released from the pro-
gesterone containing IUD . The ring 
which is being evaluated is approximate-
ly 60 mm. in diameter and resembles 
the outer rim of a diaphragm except 
that it is thicker. 
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The ring is inserted into the vagina, 
left in place for 21 days and then 
removed and rinsed clean. After seven 
days during which time the woman 
menstruates, the ring is reinserted. 
The steroid which is released from the 
ring is absorbed through the vaginal 
mucosa and acts by suppressing ovula-
tion in the same fashion as the oral 
contraceptives. The major advantage to 
the ring over the oral medication is that 
it does not require daily motivation for 
its use once it is inserted. Furthermore, 
studies with one of the rings containing 
two specific steroids, the metabolic 
changes appear to be less than those 
seen with the oral contraceptives . 
If dyspareunia were to occur due to 
the presence of the ring, it can be 
removed during intercourse and then 
replaced. 
These vaginal rings appear to carry 
considerable promise as to their ap-
plicability and acceptability for future 
use as a contraceptive agent on a 
worldwide basis. 
(b) Encapsulated microspheres : 
Biodegradeable microspheres have been 
produced into which steroid can be in-
corporated and released at varying rates . 
These microspheres are administered by 
injection and thus have the potential of 
resulting in a once a month or even less 
frequent injection for contraceptive pur-
poses . 
The advantage to this method includes 
the fact that again, it requires only oc-
casional motivation for administration, 
i.e . , one to twelve ;njections per year. 
However, the disadvantage with this 
method rests with the fact that it does 
require injection and therefore requires 
some degree of trained personnel for ad-
ministration. Furthermore, once injected, 
the medication cannot be removed from 
the body and therefore poses all of the 
problem which can be . associated with 
the injection of any long acting 
substance if untoward effects occur . 
4. Luteolytic Agents: Destruction of the 
corpus luteum on a regular monthly 
basis would assure loss of hormonal 
support of a pregnancy if it were to 
have occurred in any cycle. A monthly 
administration of a Iuteolytic agent 
would therefore result in corpus Iuteum 
destruction and the onset of withdrawal 
menses. This in fact results in an abor-
tifacient method as opposed to an an-
tifertilization one. The prostaglandins 
and their analogues have been shown to 
be extremely effective luteolytic agents 
in animals and experimentation in 
humans is progressing along similar 
lines. 
Prostaglandins have also been used 
for early pregnancy termination in the 
form of vaginal suppositories. Extensive 
side effects with many of the pro-
staglandin derivatives do occur, although 
these can be minimized or alleviated 
with the use of some of the new 
analogues. 
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5. Immunologic Contraceptive Tech-
niques: Animal experimentation has 
shown that the concept of immunizing 
the female against pregnancy is definite-
ly feasible. The major advantage of 
such a technique is the freedom which it 
provides of frequent or even daily ad-
ministration, eliminating the hazards or 
side effects of such frequent exposure. 
On the other hand, such a concept in-
troduces other problems which are at 
present not fully understood including 
reversibility, outcome of method 
failures, duration of effectiveness, in-
fluence on subsequent fertility , safety 
and widescale applicability . 
The immunologic approach to con-
traception depends upon the body's 
ability to protect itself from pregnancy 
in much the same way as it defends 
itself against bacterial infection . Such an 
approach may be directed at various 
stages in the reproductive process and 
may be accomplished by either active or 
passive immunization. The latter form is 
shortlived since it relies upon exogenous 
antibody administration and thus its ac-
tivity lasts only as long as the biological 
life of the antibody. 
Active immunization procedures are 
therefore the ones which hold promise 
as large scale contraceptive possibilities. 
It has been suggested that the ideal 
qualities of an antifertility vaccine 
would include : 
I -that it be universally effective; 
2 - intermediate in action 
(6-24 months) 
3- totally reversible, and 
4- devoid of side effects. 
Specific Immunologic Areas of 
Investigation 
A) Immunization Against Hypothalamic-
Pituitary or Gonadal Hormones 
Although the trophic hormones of the 
hypothalamus and pituitary are 
necessary for gamete development, in-
terference with their producti,on or ef-
fects results in undesirable side effects 
such as menopausal symptoms, loss of 
libido, etc. Similar effects result with 
immunization against any of the gonadal 
hormones. This avenue of approach is, 
therefore, unlikely to provide the solu-
tion to immunologic contraception. 
B) Immunization Against Spermatazoa 
Immunization against various sperm 
specific antigens such as those of the 
acrosomal cap, the midpiece or the tail 
are being evaluated. To date, however, 
only partial immunity has been achieved 
when such antigens have been ad-
ministered to the female. 
C) Immunization Against Female 
Reproductive Tract Antigens such as the 
ovum (zona pellucida), embryo and 
placenta specific antigens are currently 
being evaluated as potential targets for 
immunologic contraception. These sites 
appear to be the most promising at pres-
ent for future immunologic contraceptive 
development. 
6. Reversible Sterilization Procedures: 
Male: 
Intravasal plugs of various shapes, 
sizes and materials which can occlude 
the lumen of the vas and later be 
removed have been and are currently be-
ing evaluated. Their major disadvantages 
430 Richmond Street/Telephone 672-4720 
lies in the inability to obtain tissue in-
growth from the vas into the plug in 
order to stabilize it. The plug can 
therefore shift, resulting in the passage 
of seminal fluid beyond the plug, and 
subsequent failure. 
The ability to invert a valve much like 
a tap which could be turned on and off 
to allow the passage alternating with 
obstruction of seminal fluid flow has 
been the aim of many researchers. To 
date, no one has been able to produce 
an adequate mechanical occlusive vasal 
device. 
Female: 
a) Hysteroscopically Directed Tubal 
Plugs 
Small plugs of metal alloy and silastic 
are being evaluated for occulusion of 
the tubal ostia with a view to subse-
quent removal and re-establishment of 
fertility . These plugs are delivered by 
means of a hysteroscope into the uterine 
cavity. 
A major disadvantage to a procedure 
such as this, is the necessity for an ex-
perienced hysteroscopist to carry out the 
procedure. Furthermore, even though the 
hysteroscope is inserted into the uterine 
cavity through the cervix, the tubal ostia 
can only be visualized in approximately 
85o/o of cases. The amount of en-
dometrium present in the uterine cavity 
can also effect the visualization and 
therefore the timing of the procedure is 
critical in that it should be performed in 
the early follicular phase of the cycle. 
Sophisticated endoscopic equipment such 
as the hysteroscope makes this pro-
cedure expensive both from the stand-
point of purchasing as well as 
maintenance. 
The reversibility of such a procedure 
is still yet unproven and is in the early 
human stages of investigation at the pres-
ent time. If the techniques do prove to 
be feasible, it could then be carried out 
under local anaesthesia in a clinic set-
ting. 
b) Tubal Covers or Hoods 
Various forms of fimbria! covers have 
been developed and are continuing to be 
developed, which would act much like a 
"condom" over the fimbriated end of 
the tube preventing entry of the ovum. 
The problem which is currently being 
encountered is to find a hood which can 
be held in place over the fimbriated end 
of the tube and at the same time allow 
for transudation of tubal fluid through 
it so that a hydrosalpinx will not 
develop. The fimbria! covers which are 
currently being evaluated require a mini-
laparotomy incision and suturing in 
place with at least four stay sutures . 
This requires the use of magnification 
by loop glasses so that a very fine 
suture can be utilized which would pro-
duce less tissue reaction in the serosa of 
the tube and thus fewer adhesions . 
CONCLUSION 
Whenever one deals with the topic of 
conception and its prevention, science 
must come to grips with religious , moral 
and ethical considerations as well. The 
concept of effective and readily available 
contraception has been earmarked as a 
licence for "loose morals" and 
"promiscuity" by many. The validity of 
this statement is somewhat open to 
question. Perhaps however it is an easy 
way of covering up our deficiencies as 
parents in shaping the moral and ethical 
standards of our children. 
There is currently no single ideal con-
traceptive method available. As a result, 
the choice of any method must be based 
upon careful consideration of each in-
dividual case. The past medical and 
family histories must be evaluated and 
the patient's fears, anxieties and ap-
prehensions regarding each method con-
sidered. Only then can the risks for 
each method be weighed against the 
benefits to the individual. Selection of a 
contraceptive method can then be made 
by an informed patient with the 
guidance of her physician . 
Numerous avenues of new contracep-
tive techniques are being investigated in 
centers throughout the world . The ideal 
contraceptive still appears to be in the 
distant future. Until then, we must 
utilize the methods which are available 
to us and at the same time assure 
ourselves that the patient has adequate 
counselling and understands fully the 
implications of her final decision. 
FAILURE RATES* WITH VARIOUS BIRTH CONTROL METHODS 
TUBAL STERILIZATION 0- 0.02 
VASECTOMY 0- 0.02 
ORAL CONTRACEPTIVES 0- 0 . 1 
I.U.D. 2- 4 
CONDOM 10- 14 
DIAPHRAGM 12- 15 
CHEMICAL SPERMICIDES 4-29 
WITHDRAWAL 20-38 
RHYTHM 14-47 
NO METHOD 60- 80 
*Number of pregnancies expected per 100 couples using the method for one year. 
References - Rx Bulletin 1970 
British Medical Bulletin 
FDA Consumer 1977 
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The Seven Year Itch 
Primary biliary cirrhosis (PBC) is a 
very rare fatal disease. According to 
Dame Sheila Sherlock there were 165 
deaths certified as due to it in England 
and Wales in 1967-71'. That means that 
approximately I in 50,000,000 people 
will die of this disease assuming that 
half of the deaths will be undiagnosed . 
Or to put it another way there should 
be about 80 such deaths in Canada in a 
5 year period. The average prognosis 
from the time of diagnosis is probably 
at present about 7 years2 , so there 
should be 560 such patients in Canada 
at any one time. In 5 years the Univer-
sity Hospital , Lodon, Ontario , has 
made the diagnosis 16 times or about 3 
new cases a year. A physician in general 
practice is not likely to see one case in 
his career. 
Nevertheless it is a fascinating disease 
characterised usually by an insidious 
onset of relentless pruritus in nearly 4/ 5 
of the cases (Table 1). What is this ir-
repressible itch due to? As with so 
many diseases of obscure aetiology , 
when we don't know we suspect and 
speculate. At the time of diagnosis the 
characteristic lesion is a destruction of 
cholangioles in the portal triads in the 
midst of a dense spherical lymphocytic 
infiltrate. Sometimes a few epithelioid 
cells forming a granuloma are present 
(911Jo of cases only) . An alternative name 
for the disease is more accurate but 
more of a mouthful: chronic non-
suppurative destructive cholangitis. Why 
the bile ductules are seemingly attacked 
by lymphocytes is not known. There are 
several reasons, some g1vmg useful 
diagnostic tests, why an immunological 
attack on the cholangioles is suspected. 
The main one is that 80-90% of the pa-
tients have circulating antibodies against 
mitochondria (AMAs) while normal peo-
ple have none and people with another 
chronic liver disease, chronic active 
hepatitise, have AMAs in only 30% of 
cases 3 • This is probably an IgM which 
is often elevated and histochemically 
similar material can be seen in the le-
sion. Relatives of patients with PBC 
tend to have PBC more often and an 
increased incidence of circulating ab-
normal antibodies of various sorts• but 
if it is an "autoimmune" disease, then 
unlike other autoimmune diseases it is 
not associated with any particular HLA 
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transplantation antigen or ABO or 
Rhesus blood group 5 6 • 
Because of the interest in narrowing 
down the prognosis attempts were made 
to "stage" the progress of the disease 
by a liver biopsy with moderate suc-
cess7 "· As many such progressive in-
flammatory diseases, it develops from a 
degenerating duct cell under attack by 
antibodies or by lymphocytes, to cell 
necrosis, chronic or chronic granulo-
matous inflammation (Fig. 1) , to healing 
by fibrosis and eventually to demon-
strate cirrhosis. The lesions are 
multifocal but develop more or less 
simultaneously, so that a degree of stag-
ing is possible on the basis of mor-
phological progression of the disease . 
For the purposes of diagnosis , the 
hallmark is a liver with a striking pauci-
ty of bile ductules in portal triads, with 
occasional round foci of lymphocytes 
there, and often very slender fibrous 
septa connecting portal areas in the cir-
_rhotic s ta~e . 
Given the disappearance of bile duc-
tules, the symptomatology can be 
reasonably well accounted for. There is 
intrahepatic biliary obstruction in the 
first instance, with pruritus pre-
dominating for unknown reasons . Jaun-
dice and hypercholesterolaemia with xan-
thelasmas are also common. In this 
stage the alkaline phosphatase is 
elevated in the serum disproportionately 
to liver enzymes, as expected. There 
may be steatorrhoea and malabsorption . 
In the cirrhotic stage liver failure adds 
its symptomatology with such hormonal 
effects as amenorrhoea , acne and hir-
sutism . A bleeding tendency because of 
hypoprothrombinaemia or from varices, 
and anaemia of hypersplenism also oc-
cur. In other words PBC is one of the 
possibilities in obscure cirrhosis. 
This disease involves women in 
85-90% of cases, for no known reason. 
Our own cases show 13 women and 3 
men. The average age is 50. In our 16 
cases the average age at diagnosis was 
55 with a range from 39 to 68 years. It 
is generally accepted that the disease 
progresses relentlessly to death . Dame 
Sherlock2 reports 35 cases followed from 
diagnosis to death, for an average inter-
val from diagnosis to death of 5 V2 years 
with a wide range between 3 and 11 
years. More recent literature suggests a 
by Dr. J. V. Frei 
TABLEt 
PRESENTATION OF PRIMARY 
BILIARY CIRRHOSIS2 
Pruritus 
Pruritus 
Icterus 
Cirrhosis 
Abnormal Jab test 
Other 
OJo 
57 
20 
8 
7 
4 
4 
slightly better prognosis as anecdotally 
many cases live for more than 10 years. 
This could be due to earlier diagnosis, 
or changing criteria of diagnosis, or the 
detection of subclinical cases. It is 
because of that that perhaps a seven 
year survival is at present a realistic 
average- the seven year itch. 
-the seven year itch. 
The treatment of all diseases of 
unknown aetiology tends to be un-
satisfactory. Unlike some autoimmune 
diseases, PBC does not generally resp-
ond well to steriods, may even perhaps 
be accelerated by them. Nothing can be 
done, it seems, to affect the course of 
the disease, so therapy is aimed more at 
the prominent bothersome symptom, 
pruritus. As the biliary obstruction, 
while marked, is obviously incomplete, 
the aim is to interrupt the enterohepatic 
circulation and prevent the reabsorption 
of whatever it is that causes the 
pruritus . Oral cholestyramine and if 
more drastic measures are required, the 
creation of a biliary fistula to the out-
si de have had a modicum of success9 in 
treating pruritus in cases of the seven 
year itch. 
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Letter to the Editor 
Dear Editor, 
I would like to correct a statement made by Maureen McConnell in "Hip-
pocratic Council News" (Vol. 49, No.1, March, 1979). 
The increase in clerkship stipend from $1200 to $1500 was engineered by the 
O.F.M.S.S. (Ontario Federation of Medical Student Societies), and not the 
S.S.O.M.A. 
The S.S.O.M.A. was certainly very helpful in preparing a comparative survey 
of medical student funding across Canada and it was armed with this survey and 
other facts, figures and arguments, that Anne Fleming (President U. of T.M.S.S.) 
and I met with Mr. Timbrell last fall. 
That meeting closed with an undertaking by O.F.M.S.S. to provide current 
year (1978-79) statistics on funding and with an undertaking by the Ministry to 
meet with us again to discuss the amount, if any, of the increase. Shortly 
thereafter an increase of $300 was announced although it has remained the inten-
tion of the O.F.M.S.S. to proceed according to the understanding of our first 
meeting with a view to a total increase of at least $600 - the figure which more 
nearly approaches the shortfall between available funding and need. 
Yours very truly, 
Jeff Coleman. Meds '79 
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BEEP! BEEP! BEEP! 
THE SOUND OF BUSINESS 
One of the greatest thieves of time 
are hours spent tracing people 
to answer business calls. 
A POCKET PAGER COULD SOLVE YOUR PROBLEMS 
For only pennies per day - CAN YOU AFFORD NOT TO INQUIRE? 
679-0123 
'THE PEOPLE FINDERS' 
Are you thinking about 
leasing? 
Any information 
on any make or model 
Phone 434-57 41 
TEDD SMITH 
Leasing Manager 
Central Chev- Olds 
Ltd. 
128 Fullarton St., London 
DEAN RUSSELL LIMITED 
DRUG AND SURGICAL SUPPLY 
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PHONE (519) 434-4565 
PHYSICIAN 
NEEDS -
• Lab Coats 
• Blood Pres-
sure Sets 
• Microscopes 
• Stethoscopes 
• Dissecting 
Kits 
• Diagnostic 
Sets 
• Needles 
• Syringes 
• Gauze, 
Etc. 
Surgical Division 
f 87 HYMAN STREET 
PHONE (5f9) 433·9268 
RENTAL 
DIVISION 
• Wheelchairs 
• Walkers 
• Crutches 
• Baby 
Scales 
• Oxygen 
.. Equipment 
• Suction Machine 
• Hospital Beds 
HOME CARE NEEDS 
Urinals - Incontinent Pants -- Ostomy Supplies Texas 
Catheters - Bedside Bags Incontinent Pads Elastic 
Stockings - Knee, Wrist, Elbow and Ankle Braces Body 
Belts - Back Braces - Cervical Collars - Commodes -
Everest & Jennings Wheel Chairs and Accessories Crutches 
Canes - Walkers - Geriatric Chairs - Elevated Toilet Seats 
Grab Bars - Bath Tub Rails Bath Tub Seats Air 
Cushions - Hospital Beds 
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